Rabbit F(ab)2 anti-Dog IgG (H+L)-Biotin, MinX none

Artikelnummer: DNA-SEC-183676
Artikelname: Rabbit F(ab)2 anti-Dog IgG (H+L)-Biotin, MinX none
Artikelnummer: DNA-SEC-183676
Hersteller Artikelnummer: SEC-183676
Alternativnummer: DNA-SEC-183676
Hersteller: dianova
Wirt: Rabbit
Kategorie: Antikörper
Applikation: ELISA,IHC,WB
Spezies Reaktivität: Canine
Immunogen: Dog IgG whole molecule
Konjugation: Biotin
Alternative Synonym: Rabbit F(ab)2 Anti-Dog Biotin Conjugated Antibody, Rabbit Fab2 Anti-Dog Antibody Biotin Conjugation, Rabbit Fab2 Anti-Dog Antibody Biotin Conjugation
Format: F(ab')2
Spezifität: IgG (H+L)
Minimale Kreuzreaktivität (MinX): no cross-adsorbtion
F(ab)2 Antibody was generated by enzymatic cleavage and subsequent separation from the Fc fragment. Because of their smaller size, F(ab)2 fragments offer several advantages over intact antibodies for use in certain immunochemical techniques and experimen
Klonalität: Polyclonal
Konzentration: 1 mg/mL
Isotyp: Ig
Puffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Reinheit: This product was prepared from monospecific antiserum by immunoaffinity chromatography using Dog IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities, pepsin digestion and chromatographic separation.   Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Biotin, anti-Rabbit Serum, Dog IgG and Dog Serum.  No reaction was observed against anti-Pepsin or anti-Rabbit IgG F(c).
Formulierung: Lyophilized
Formel: 20 mM K3PO4,150 mM NaCl,pH 7,2,lyophilisate,Azide/BSA free
Target-Kategorie: Dog
Antibody Type: Secondary Antibody
Application Verdünnung: ELISA Dilution: 1:20,000 - 1:100,000, Immunohistochemistry Dilution: 1:1,000-1:5,000, Western Blot Dilution: 1:2,000-1:10,000
Anwendungsbeschreibung: This product is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.